Home>>Signaling Pathways>> Microbiology & Virology>> HIV>>2',3'-Dideoxyadenosine
2',3'-Dideoxyadenosine Catalog No.GC33994

Size Price Stock Qty
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 4097-22-7 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES NC1=C(N=CN2[C@H]3CC[C@H](O3)CO)C2=NC=N1
Formula C10H13N5O2 M.Wt 235.24
Solubility H2O: 100 mg/mL (425.10 mM); DMSO: 100 mg/mL (425.10 mM) Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



2',3'-Dideoxyadenosine is an inhibitor of HIV replication[1]. Antiretroviral activity[1]. Antiviral efficacy[1].

2',3'-Dideoxyadenosine inhibits HIV-1 and simian immunodeficiency virus (SIV) in MT-4 cells with EC50s of 5.27 and 5.3 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in human T-lymphocyte CEM cells with EC50s of 4 μM and 8 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in Molt 4/C8 cells with EC50s of 4 μM and 5.5 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in C8166 cells with EC50s of 17 μM and 22 μM, respectively. 2',3'-Dideoxyadenosine inhibits murine sarcoma virus (MSV) in C3H/3T3 cells with an EC50 of 24 μM[1].

[1]. Balzarini J, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997 Jun 30;410(2-3):324-8.